MARKET

VOR

VOR

Vor Biopharma Inc.
NASDAQ
11.64
-1.44
-11.01%
After Hours: 11.60 -0.04 -0.34% 19:49 01/02 EST
OPEN
13.20
PREV CLOSE
13.08
HIGH
13.60
LOW
11.63
VOLUME
1.18M
TURNOVER
--
52 WEEK HIGH
65.80
52 WEEK LOW
2.622
MARKET CAP
450.70M
P/E (TTM)
-0.0301
1D
5D
1M
3M
1Y
5Y
1D
Vor Biopharma CDO Departs, Transition Support Planned
TipRanks · 23h ago
Vor Biopharma Announces Separation Agreement With Chief Development Officer Qing Zuraw
Reuters · 23h ago
Getty Images, Torm, and More Stocks See Action From Activist Investors
Barron‘s · 1d ago
Weekly Report: what happened at VOR last week (1222-1226)?
Weekly Report · 12/29/2025 09:08
*Vor Biopharma: Board Appointments Follow Recently Announced PIPE Financing >VOR
Dow Jones · 12/23/2025 21:03
Vor Biopharma Adds Andrew Levin and Wouter Joustra to Board
Reuters · 12/23/2025 21:01
VOR BIO APPOINTS RA CAPITAL’S ANDREW LEVIN, M.D., PH.D., AND FORBION’S WOUTER JOUSTRA TO BOARD OF DIRECTORS
Reuters · 12/23/2025 21:01
*Vor Biopharma Names Andrew Levin, Wouter Joustra to Board
Dow Jones · 12/23/2025 21:01
More
About VOR
Vor Biopharma Inc. is a clinical-stage biotechnology company transforming the treatment of autoimmune diseases. The Company is focused on rapidly advancing telitacicept, a dual-target fusion protein, through Phase III clinical development and commercialization to address serious autoantibody-driven conditions worldwide. Telitacicept is an investigational recombinant fusion protein designed to treat autoimmune diseases by selectively inhibiting BLyS (BAFF) and APRIL - two cytokines essential to B cell and plasma cell survival. This dual-target mechanism reduces autoreactive B cells and autoantibody production, key drivers of autoimmune pathology. Telitacicept is approved in China for systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and generalized myasthenia gravis (gMG). A global Phase III clinical trial in gMG is underway across the United States, Europe, and South America to support potential approval in the United States and Europe.

Webull offers Vor Biopharma Inc stock information, including NASDAQ: VOR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VOR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading VOR stock methods without spending real money on the virtual paper trading platform.